OncoMatch/Clinical Trials/NCT05847348
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Is NCT05847348 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies 68Ga-PSMA-11 for biochemical recurrence of malignant neoplasm of prostate.
Treatment: 68Ga-PSMA-11 — This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prostate Cancer
Prior therapy
Must have received: radical prostatectomy
have undergone radical prostatectomy
Must have received: radical radiotherapy
have undergone...radical radiotherapy
Cannot have received: radionuclides
Exception: interval of less than 10 physical half-lives before the administration of 68Ga-PSMA-11
prior use of radionuclides with an interval of less than 10 physical half-lives before the administration of 68Ga-PSMA-11
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify